专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010046783A2 A1 MOIETY OF CHOLERA TOXIN A SUBUNIT AS AN ADJUVANT FOR MUCOSAL AND SYSTEMIC VACCINES 审中-公开
标题翻译： A1作为粘膜和系统性疫苗的辅助剂的儿茶素毒素亚型
公开(公告)号：WO2010046783A2
公开(公告)日：2010-04-29
申请号：PCT/IB2009007461
申请日：2009-10-21
申请人： INTERNAT VACCINE INST , CZERKINSKY CECIL , SONG MANKI
发明人： CZERKINSKY CECIL , SONG MANKI
IPC分类号： C07K19/00 , A61P37/04
CPC分类号： C12N9/1051 , A61K39/12 , A61K39/21 , A61K39/39 , A61K2039/541 , A61K2039/55544 , C07K2319/10 , C07K2319/55 , C12N2760/16134
摘要： The present invention relates to cholera toxin CTA1protein fragments, adjuvant compositions, and methods relating to adjuvants for vaccines. The invention also relates to using recombinant CTA1 fragments conjugated to a polypeptide containing a protein transduction domain or cell-penetrating peptide as an immunomodulator.
摘要翻译：本发明涉及霍乱毒素CTA1蛋白片段，佐剂组合物和与疫苗佐剂有关的方法。本发明还涉及使用与含有蛋白质转导结构域或细胞穿透肽的多肽缀合的重组CTA1片段作为免疫调节剂。

2. 发明申请

WO02093998A9 SUPPRESSION OF ALLERGIC REACTIONS BY TRANSDERMAL ADMINISTRATION OF ALLERGENS IN CONJUNCTION WITH OR CONJUGATED TO TOXIN SUBUNITS OR FRAGMENTS THEREOF 审中-公开
标题翻译：过敏反应的抑制作用是通过与过氧化物连接或连接到毒素亚基或其片段的过敏原
公开(公告)号：WO02093998A9
公开(公告)日：2005-05-26
申请号：PCT/IB0203053
申请日：2002-05-23
申请人： DUOTOL AB , HOLMGREN JAN , CZERKINSKY CECIL
发明人： HOLMGREN JAN , CZERKINSKY CECIL
IPC分类号： A61K39/00 , A61K38/16 , A61K39/35 , A61K39/36 , A61K39/39 , A61K45/06 , A61K47/48 , A61P37/06 , A61P37/08 , C07K14/185 , A61K9/70 , A61K39/106 , A61K39/108 , C07K19/00
CPC分类号： A61K45/06 , A61K38/164 , A61K39/35 , A61K39/36 , A61K47/6415 , A61K47/646 , A61K2039/55544 , A61K2039/6037 , A61K2300/00
摘要： The present invention discloses the use of the non-toxic cell-binding B subunit of CT (CTB), and holotoxin CT that is devoid of ADP-ribosylating activity, as adjuvants for enhancing transcutaneous immune response to a co-administered protein allergen. It was found that topical administration of CTB to mice induced serum antibody response against itself comparable to those evoked by CT, but was inefficient at promoting systemic antibody responses against an admixed prototype protein allergen. To the contrary co-administration of either CT or CTB with allergen led to vigorous antigen-specific T cell proliferative responses in lymph nodes draining the cutaneous site of administration and at distant systemic sites. Consistent with these observations, it was found that CTB selectively potentiated Th1-driven responses without affecting Th2-dependent responses. Cutaneously applied CT enhanced serum IgE responses to a co-administered allergen, while CTB partially suppressed epicutaneously induced IgE responses to the same allergen.
摘要翻译：本发明公开了CT（CTB）的无毒性细胞结合B亚基和缺乏ADP-核糖基化活性的全毒素CT作为用于增强对共同施用的蛋白质变应原的经皮免疫应答的佐剂。已经发现CTB局部给予小鼠诱导的血清抗体对本身的反应与CT诱发的抗体相当，但在促进针对混合的原型蛋白变应原的全身抗体应答方面效率低下。相反，CT或CTB与变应原的共同给药导致排泄皮肤部位和淋巴系统部位的淋巴结中的抗原特异性T细胞增殖反应。与这些观察结果一致，发现CTB选择性增强Th1驱动的反应，而不影响Th2依赖性反应。皮肤应用CT增强了对共同施用的变应原的血清IgE反应，而CTB部分抑制外源性诱导相同过敏原的IgE应答。

3. 发明申请

WO2010046778A3 NOVEL SHIGELLA FROTEIN ANTIGENS AND METHODS 审中-公开
公开(公告)号：WO2010046778A3
公开(公告)日：2010-04-29
申请号：PCT/IB2009/007385
申请日：2009-10-21
申请人： INTERNATIONAL VACCINE INSTITUTE , CZERKINSKY, Cecil , KIM, Dong, Wook
发明人： CZERKINSKY, Cecil , KIM, Dong, Wook
IPC分类号： C07K14/25 , C12N15/31 , C12N15/63
摘要： The present invention relates to protein antigens IcsP2 and SigA2 from Shigella that are common among numerous Shigella types and species and which can protect against shigellosis or other enteric infections when administered as vaccines. In addition, the present invention relates to antigens that are in common between Shigella species and enteroinvasive Escherichia coli (EIEC). The invention also relates to the use of antibodies raised against these antigens and of DNA probes for use in the diagnosis of Shigella and EIEC infections.

4. 发明申请

WO2005082408A3 A VACCINE COMPOSITION COMPRISING AN IMMUNOADJUVANT COMPOUND CONSISTING OF A RHO GTPASE FAMILY ACTIVATOR 审中-公开
标题翻译：包含RHO蛋白家族激活剂的免疫化合物的疫苗组合物
公开(公告)号：WO2005082408A3
公开(公告)日：2005-11-10
申请号：PCT/EP2005002105
申请日：2005-02-25
申请人： INST NAT SANTE RECH MED , LEMICHEZ EMMANUEL , CZERKINSKY CECIL , ANJUERE FABIENNE , BOQUET PATRICE , MUNRO PATRICK , FLATAU GILLES
发明人： LEMICHEZ EMMANUEL , CZERKINSKY CECIL , ANJUERE FABIENNE , BOQUET PATRICE , MUNRO PATRICK , FLATAU GILLES
IPC分类号： A61K39/39 , A61K39/108 , A61K39/00 , A61K39/02 , A61K39/10 , A61K39/106 , A61K39/112
CPC分类号： A61K39/39 , A61K2039/55516
摘要： This invention is based on the experimental finding that activators of Rho GTPases, namely the cytotoxic necrotizing factor 1 (CNF1), and DNT bear immunostimulatory properties towards the systemic response to orally administered ovalbumine. This invention concerns a vaccine composition comprising an immunoadjuvant compound, wherein said immunoadjuvant compound consists of a Rho GTPase activator.
摘要翻译：本发明基于实验发现，Rho GTP酶的活化剂，即细胞毒性坏死因子1（CNF1）和DNT对口服给药的卵白蛋白具有针对全身反应的免疫刺激性。本发明涉及包含免疫佐剂化合物的疫苗组合物，其中所述免疫佐剂化合物由Rho GTPase激活剂组成。

5. 发明申请

WO2010046783A3 A1 MOIETY OF CHOLERA TOXIN A SUBUNIT AS AN ADJUVANT FOR MUCOSAL AND SYSTEMIC VACCINES 审中-公开
公开(公告)号：WO2010046783A3
公开(公告)日：2010-04-29
申请号：PCT/IB2009/007461
申请日：2009-10-21
申请人： INTERNATIONAL VACCINE INSTITUTE , CZERKINSKY, Cecil , SONG, Manki
发明人： CZERKINSKY, Cecil , SONG, Manki
IPC分类号： C07K19/00 , A61P37/04
摘要： The present invention relates to cholera toxin CTA1protein fragments, adjuvant compositions, and methods relating to adjuvants for vaccines. The invention also relates to using recombinant CTA1 fragments conjugated to a polypeptide containing a protein transduction domain or cell-penetrating peptide as an immunomodulator.

6. 发明申请

WO1990004182A1 A METHOD FOR SIMULTANEOUS DETECTION OF DIFFERENT TYPES OF ANTIBODIES AND/OR ANTIGENS PRODUCED BY INDIVIDUAL CELLS 审中-公开
标题翻译：一种用于同时检测由个体细胞产生的抗体和/或抗原的不同类型的方法
公开(公告)号：WO1990004182A1
公开(公告)日：1990-04-19
申请号：PCT/SE1989000565
申请日：1989-10-13
申请人： VIROVAHL S.A. , VAHLNE, Anders , CZERKINSKY, Cecil
发明人： VIROVAHL S.A.
IPC分类号： G01N33/577
CPC分类号： G01N33/54306
摘要： A method for detection of antibodies and/or antigens secreted and/or released by individual cells, at which a cell suspension is brought in contact with a solid carrier. After that or simultaneously therewith are added at least two different types of other antibodies directed against and having an ability to bind to the antibodies or antigens resp. to be detected, and which other antibodies are provided with different enzymes. The corresponding number of indicator substances is then added having different staining, effect for simultaneous detection of the different types of antibodies and/or antigens by evaluation of spots of distinct colours remaining on the solid carrier. According to the embodiment two solid carriers are used, at which antigens and/or antibodies of the same or different type are bound to opposed surfaces of the carriers and the cell suspension is applied between these surfaces.
摘要翻译：用于检测由个体细胞分泌和/或释放的抗体和/或抗原的方法，其中使细胞悬浮液与固体载体接触。之后或同时加入至少两种不同类型的针对和具有结合抗体或抗原的能力的其他抗体。待检测，哪些其他抗体具有不同的酶。然后添加相应数量的指示物质，具有不同的染色，通过评估残留在固体载体上的不同颜色的斑点同时检测不同类型的抗体和/或抗原的效果。根据实施方案，使用两种固体载体，其中相同或不同类型的抗原和/或抗体与载体的相对表面结合，并且在这些表面之间施加细胞悬浮液。

7. 发明申请

WO02093998A2 SUPPRESIION OF ALLERGIC REACTIONS BY TRANSDERMAL ADMINISTRATION OF ALLERGENS IN CONJUNCTION WITH OR CONJUGATED TO TOXIN SUBUNITS OR FRAGMENTS THEREOF 审中-公开
标题翻译：过敏反应的抑制作用是通过与过氧化物连接或连接到毒素亚基或其片段的过敏原
公开(公告)号：WO02093998A2
公开(公告)日：2002-11-28
申请号：PCT/IB0203053
申请日：2002-05-23
申请人： DUOTOL AB , HOLMGREN JAN , CZERKINSKY CECIL
发明人： HOLMGREN JAN , CZERKINSKY CECIL
IPC分类号： A61K39/00 , A61K38/16 , A61K39/35 , A61K39/36 , A61K39/39 , A61K45/06 , A61K47/48 , A61P37/06 , A61P37/08 , C07K14/185
CPC分类号： A61K45/06 , A61K38/164 , A61K39/35 , A61K39/36 , A61K47/6415 , A61K47/646 , A61K2039/55544 , A61K2039/6037 , A61K2300/00
摘要： The present invention discloses the use of the non-toxic cell-binding B subunit of CT (CTB), and holotoxin CT that is devoid of ADP-ribosylating activity, as adjuvants for enhancing transcutaneous immune response to a co-administered protein allergen. It was found that topical administration of CTB to mice induced serum antibody response against itself comparable to those evoked by CT, but was inefficient at promoting systemic antibody responses against an admixed prototype protein allergen. To the contrary co-administration of either CT or CTB with allergen led to vigorous antigen-specific T cell proliferative responses in lymph nodes draining the cutaneous site of administration and at distant systemic sites. Consistent with these observations, it was found that CTB selectively potentiated Th1-driven responses without affecting Th2-dependent responses. Cutaneously applied CT enhanced serum IgE responses to a co-administered allergen, while CTB partially suppressed epicutaneously induced IgE responses to the same allergen.
摘要翻译：本发明公开了CT（CTB）的无毒性细胞结合B亚基和缺乏ADP-核糖基化活性的全毒素CT作为用于增强对共同施用的蛋白质变应原的经皮免疫应答的佐剂。已经发现CTB局部给予小鼠诱导的血清抗体对本身的反应与CT诱发的抗体相当，但在促进针对混合的原型蛋白变应原的全身抗体应答方面效率低下。相反，CT或CTB与变应原的共同给药导致排泄皮肤部位和淋巴系统部位的淋巴结中的抗原特异性T细胞增殖反应。与这些观察结果一致，发现CTB选择性增强Th1驱动的反应，而不影响Th2依赖性反应。皮肤应用CT增强了对共同施用的变应原的血清IgE反应，而CTB部分抑制外源性诱导相同过敏原的IgE应答。

8. 发明申请

WO2010046778A2 NOVEL SHIGELLA FROTEIN ANTIGENS AND METHODS 审中-公开
标题翻译：新西兰冷冻抗原和方法
公开(公告)号：WO2010046778A2
公开(公告)日：2010-04-29
申请号：PCT/IB2009007385
申请日：2009-10-21
申请人： INTERNAT VACCINE INST , CZERKINSKY CECIL , KIM DONG WOOK
发明人： CZERKINSKY CECIL , KIM DONG WOOK
IPC分类号： C07K14/25 , C12N15/31 , C12N15/63
CPC分类号： C07K14/25 , A61K39/0283 , A61K2039/55566 , A61K2039/6037 , A61K2039/6087
摘要： The present invention relates to protein antigens IcsP2 and SigA2 from Shigella that are common among numerous Shigella types and species and which can protect against shigellosis or other enteric infections when administered as vaccines. In addition, the present invention relates to antigens that are in common between Shigella species and enteroinvasive Escherichia coli (EIEC). The invention also relates to the use of antibodies raised against these antigens and of DNA probes for use in the diagnosis of Shigella and EIEC infections.
摘要翻译：本发明涉及许多志贺氏菌类型和物种中常见的来自志贺氏菌的蛋白质抗原IcsP2和SigA2，并且当作为疫苗施用时可以防止志贺氏菌病或其他肠道感染。此外，本发明涉及在志贺氏菌属种群和肠内侵袭性大肠杆菌（EIEC）之间共同的抗原。本发明还涉及使用针对这些抗原产生的抗体和DNA探针用于诊断志贺氏菌和EIEC感染。

9. 发明申请

WO2002093998A3 SUPPRESSION OF ALLERGIC REACTIONS BY TRANSDERMAL ADMINISTRATION OF ALLERGENS IN CONJUNCTION WITH OR CONJUGATED TO TOXIN SUBUNITS OR FRAGMENTS THEREOF 审中-公开
公开(公告)号：WO2002093998A3
公开(公告)日：2002-11-28
申请号：PCT/IB2002/003053
申请日：2002-05-23
申请人： DUOTOL AB , HOLMGREN, Jan , CZERKINSKY, Cecil
发明人： HOLMGREN, Jan , CZERKINSKY, Cecil
IPC分类号： A61K39/39
摘要： The present invention discloses the use of the non-toxic cell-binding B subunit of CT (CTB), and holotoxin CT that is devoid of ADP-ribosylating activity, as adjuvants for enhancing transcutaneous immune response to a co-administered protein allergen. It was found that topical administration of CTB to mice induced serum antibody response against itself comparable to those evoked by CT, but was inefficient at promoting systemic antibody responses against an admixed prototype protein allergen. To the contrary co-administration of either CT or CTB with allergen led to vigorous antigen-specific T cell proliferative responses in lymph nodes draining the cutaneous site of administration and at distant systemic sites. Consistent with these observations, it was found that CTB selectively potentiated Th1-driven responses without affecting Th2-dependent responses. Cutaneously applied CT enhanced serum IgE responses to a co-administered allergen, while CTB partially suppressed epicutaneously induced IgE responses to the same allergen.

10. 发明申请

WO1995010301A1 IMMUNOLOGICAL TOLERANCE-INDUCING AGENT 审中-公开
标题翻译：免疫耐受诱导剂
公开(公告)号：WO1995010301A1
公开(公告)日：1995-04-20
申请号：PCT/SE1994000941
申请日：1994-10-07
申请人： HOLMGREN, Jan , CZERKINSKY, Cecil
IPC分类号： A61K39/385
CPC分类号： A61K39/001 , A61K39/0008 , A61K47/646 , A61K2039/542 , A61K2039/6037 , Y10S424/81 , Y10S514/828 , Y10S514/885 , Y10S530/868
摘要： An immunological tolerance-inducing agent comprising a mucosabinding molecule linked to a specific tolerogen is disclosed. Further, a method of inducing immunological tolerance in an individual against a specific antigen, including hapten, which causes an unwanted immune response in said individual comprising administration by a mucosal route of an immunologically effective amount of an immunological tolerance-inducing agent of the invention to said individual, is described.
摘要翻译：公开了包含与特异性耐受原相连的粘膜粘附分子的免疫耐受诱导剂。此外，一种针对特定抗原（包括半抗原）诱导免疫耐受的方法，其引起所述个体中的不需要的免疫应答，包括通过粘膜途径施用免疫有效量的本发明的免疫耐受诱导剂至说个人，被描述。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式